Rezolute Announces Completion of Enrollment in Phase 3 upLIFT Study of Ersodetug in Tumor Hyperinsulinism

Rezolute, Inc. (RZLT) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Rezolute Announces Completion of Enrollment in Phase 3 upLIFT Study of Ersodetug in Tumor Hyperinsulinism Topline results expected mid-December 2026 REDWOOD CITY, Calif., October 14, 2026 – Rezolute, Inc. (Nasdaq: RZLT) (Rezolute or Company), a late-stage ultra-rare

Event · Clinical / regulatory
Product
ersodetug
Milestone
trial start
Indication
tumor HI

Facts are quoted from the filing text and checked against it.

Original reporting
Published Oct 14, 2026, 9:11 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 14, 2026, 9:15 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$RZLT
Neutral
high confidence
Mentioned
$RZLT
Relevance
8/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$RZLTNeutralMed
01

Why it matters

The enrollment completion signals progress toward a pivotal regulatory filing, but investors await efficacy data.

02

Market read

The news is a primary disclosure of a clinical‑trial milestone, offering limited immediate trading impetus but setting the stage for future price moves.

03

What to watch

Potential competition from other hyperinsulinism therapies and regulatory timelines.

Relevance 8/10Novelty 8/10Timing: today

Background

Rezolute (Nasdaq: RZLT) is a late‑stage biotech focused on ultra‑rare hyperinsulinism disorders.

Company-level read

Ticker impact

$RZLTNeutralHigh confidence
Context

Rezolute announced full enrollment in its Phase 3 upLIFT study of ersodetug for tumor hyperinsulinism.

Expected impact

potential upside if Phase 3 results meet efficacy endpoints

Evidence & confidence

Enrollment is a key trial step; investors price in future data, but no immediate result yet.

Market effects

Positive trial progress could boost sentiment in the ultra‑rare disease biotech sector.

Limited to U.S. biotech investors; no broader regional effect.

Modest; may attract attention from global rare‑disease investors.

Counterpoint

If Phase 3 data miss targets, the enrollment milestone could be a false positive for the stock.

Key entities

  • Rezolute, Inc.

    Biotech developing ersodetug for tumor hyperinsulinism.

  • Dr. Brian Roberts

    Chief Medical Officer of Rezolute, quoted on the milestone.

Related articles

$RZLTMed

Wedbush raises Rezolute stock price target on tumor trial data

Wedbush raised its price target for Rezolute Inc. (RZLT) to $10 from $6, citing positive Phase 3 trial data. The new target suggests 179% upside from the current $3.58 share price. The firm increased its success probability for hyperinsulinism treatments and adjusted its revenue forecasts. Rezolute recently completed enrollment in a Phase 3 study and has strong liquidity, according to InvestingPro.

$RZLTHighAI 8/10

Why is Rezolute stock surging today?

Rezolute's stock rose 7.8% pre-market after reporting positive Phase 3 trial results for ersodetug and a $100M equity offering at $3.87/share. The trial met its primary endpoint, with 13 of 16 participants reducing IV glucose needs. The offering, led by Frazier Life Sciences, is expected to close by November 16. The company plans FDA discussions for both indications in Q1 2027.